Sanofi has made a strategic move by acquiring Dynavax Technologies for $2.2 billion, enhancing its vaccine offerings and addressing the growing demand for immunization solutions.
Dynavax’s Innovative Shingles Vaccine
Dynavax is currently developing Z-1018, a shingles vaccine that has entered phase 1/2 trials. Early results indicate that Z-1018 may be as effective as the widely used Shingrix vaccine, yet with significantly fewer injection site reactions among adults aged 50 to 69.
Shingles, a painful condition caused by the varicella zoster virus, affects approximately one in three adults over their lifetime. Symptoms can include a painful rash and, in severe cases, long-lasting nerve pain or serious complications like eye infections and neurological issues.
Positive Phase 1/2 Trial Results
The initial part of the phase 1/2 study revealed promising topline results for Z-1018, demonstrating immunogenicity on par with Shingrix. The trial enrolled approximately 40 participants in each of the ten Z-1018 dosage groups, alongside a control group receiving Shingrix. Importantly, all tested dosages were well-tolerated, exhibiting fewer adverse reactions than Shingrix.
Dynavax has now progressed to part 2 of the trial, focusing on adults aged 70 and older. This phase will involve around 324 healthy participants who will receive two doses spaced eight weeks apart. Results are anticipated in the latter half of 2026.
Complementary Vaccine Offerings
Beyond its shingles candidate, Dynavax also markets HEPLISAV-B, an innovative adult hepatitis B vaccine that combines the hepatitis B surface antigen with a proprietary TLR 9 agonist adjuvant. This combination enhances the immune response and is currently under review by the FDA for use in adults undergoing hemodialysis.
Additionally, Dynavax’s pipeline includes an oral COVID-19 vaccine, a plague vaccine, a Lyme disease vaccine, and a pandemic flu vaccine targeting H5N1.
Strategic Fit for Sanofi
Sanofi’s acquisition of Dynavax underscores the company’s commitment to expanding its vaccine portfolio. Thomas Triomphe, Sanofi’s Executive Vice President of Vaccines, expressed enthusiasm for the acquisition, noting that Dynavax’s offerings enhance Sanofi’s existing capabilities and provide new options for global vaccination efforts.
In the third quarter of 2025, Sanofi reported a 78% decline in vaccine sales compared to the same period in 2024, primarily due to reduced demand for influenza vaccines. As a major player in the flu vaccine market, offering products like Fluzone and Flublok, this acquisition could help stabilize and rejuvenate Sanofi’s vaccine sales.
Expanding the Pipeline
Sanofi is also advancing several late-stage vaccine candidates, including Fluzone high dose for individuals over 50 and vaccines targeting yellow fever, pneumococcal disease, and rabies. Moreover, the company is conducting phase 2 trials for vaccines against meningitis and mRNA platforms for RSV and flu.
The acquisition is expected to close in the first quarter of this year, positioning Sanofi to capitalize on the growing vaccine market.
Key Takeaways
- Sanofi’s acquisition of Dynavax for $2.2 billion aims to enhance its vaccine portfolio, particularly with the shingles vaccine Z-1018.
- Z-1018 shows comparable effectiveness to Shingrix with fewer side effects, making it a promising addition to the market.
- Dynavax’s diverse pipeline includes vaccines for hepatitis B and COVID-19, complementing Sanofi’s existing offerings.
- The acquisition reflects Sanofi’s strategy to recover from declining vaccine sales and meet global immunization needs.
In conclusion, Sanofi’s acquisition of Dynavax not only enriches its vaccine offerings but also strategically positions the company to respond to evolving public health demands. With promising products like Z-1018 in the pipeline, Sanofi is poised to strengthen its role in global vaccination efforts.
Read more → www.managedhealthcareexecutive.com